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Abstract. – OBJECTIVE: In polycythaemia ve-
ra (PV) and essential thrombocythaemia (ET),
the life expectancy of the patients is greatly af-
fected by thrombotic events. An investigation
was performed of the potential association of
PV/ET, and thrombotic complications with car-
diovascular (CV) risk factors, a leukocyte count
at the haematological diagnosis > 11.1 G/L, and
the JAK2V617F mutation.
PATIENTS AND METHODS: In the period
1998-2011, 128 women with a median age of 62
years were enrolled.
RESULTS: The risk of thrombotic events before
the diagnosis was 32.8% (42/128), while in the fol-
low-up period it was 10.2% (13/128).The difference
in the probability of thrombosis-free survival be-
tween those with at most one CV risk factor and
those with two or more CV risk factors was signifi-
cant (p = 0.005). The presence of two or more CV
risk factors (univariate: p = 0.011; multivariate: rel-
ative risk: 4.728, 95% CI 1.312-17.040; p = 0.018)
significantly increased the risk of thrombosis. Uni-
variate analyses revealed that high blood pressure
(p = 0.001), hyperlipidaemia (p = 0.005) and ciga-
rette smoking (p = 0.051) were associated with a
significantly higher risk of thrombosis. Analyses
of the influence of the leukocyte count (univariate:
p = 0.424; multivariate: relative risk: 1.407, 95% CI
0.359-5.507; p = 0.624) and the JAK2V617F muta-
tion (univariate: p = 0.367; multivariate: relative
risk: 1.428, 95% CI 0.316-6.460; p = 0.643) on sub-
sequent thrombotic complications resulted in a
non-signicant tendency.
CONCLUSIONS: Female patients who display
CV risk factors (high blood pressure, hyperlipi-
daemia and/or cigarette smoking) and PV or ET
may well be at a higher risk of thrombotic events
and require special consideration as concerns
as the prevention and management of thrombot-
ic events.
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Introduction
Congenital thrombophilias have been demon-
strated to be risk factors for venous thrombosis,
while acquired thrombophilias such as antiphos-
pholipid antibody syndrome, hyperhomocysti-
naemia and polycythaemias (e.g. polycythaemia
vera (PV)) may increase the risk of both arterial
and venous thrombosis1-3. PV and essential
thrombocythaemia (ET) are listed by the World
Health Organization as chronic Philadelphia
chromosome-negative myeloproliferative neo-
plasms (MPNs), but they can be regarded as rare
acquired thrombophilias4-6. In PV and ET, the
risk of thrombohaemorrhagic complications
(which ranges between 12% and 39%) is consid-
ered to be one of the most important key predic-
tors of the otherwise quite normal life expectancy
in these patients7-9. Thrombotic events related to
MPNs may affect the arteries (e.g. myocardial in-
farction, ischaemic stroke or a transient is-
chaemic attack) or the veins (e.g. visceral vein
thrombosis, cerebral sinus and venous thrombo-
sis, deep vein thrombosis or a pulmonary em-
bolism). In younger patients, with a female pre-
dominance, the most common cause in splanch-
2014; 18: 3810-3818
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Characteristics Data
Patients, total no. 128
PV 56
ET 72
Median follow-up (months) 43.63 (0.59-180)
Median age at diagnosis 62 (14-95)
Median red blood cell count at diagnosis 4.95 (2.66-10.81)
Median platelet count at diagnosis 518 (65-2240)
Conventional risk factors
Age > 60 72 (56.3%)
Prior thrombotic events 42 events (in 37 patients, 28.9%)
JAK2 V617F positivity (%) 84 (65.63%)
Treatment, patient no. (%)
No treatment 23 (17.97%)
Antiplatelets 48 (37.50%)
Hydroxyurea (alone or in combination with antiplatelets) 55 (42.97%)
Phlebotomy (haematocrit target < 45%) 23 (17.97%)
Table I. Main characteristics of the study population.
pact of major CV factors (hypertension, ciga-
rette smoking, diabetes mellitus, obesity and
hyperlipidaemia), leukocytosis and the presence
of the JAK2 V617F mutation on the occurrence
of thrombotic events after the haematological
diagnosis among a female population of PV and
ET patients. In the current report, we evaluate
the contributions of the CV risk factors in
thrombotic complications of ET/PV as previ-
ously reported in multicentric studies; and be-
sides the overall association, we separately
analyse the predictive potential of tobacco use,
hypertension, diabetes mellitus, and additional-
ly hyperlipidaemia and obesity. We also analyse
the thrombosis-free survival in the case of the
CV risk factors, which is not common in the rel-
evant literature.
Patients and Methods
Patients and Data Collection
Patients were selected from the chronic MPN
DNA bank of the Institute of Medical Genetics.
A review of 561 DNA analysis results revealed
56 PV and 72 ET female patients with a median
age of 62 years (range: 14-95 years) diagnosed at
the 2nd Department of Internal Medicine between
1998 and 2011 (Table I, Figures 1 and 2). In the
view of the wide age range of 14-95 years, the
CV risk factors, the distribution of the diagnosis
of ET and PV and thrombotic complications dur-
ing the follow-up period is depicted as a function
of the patients’ age in Figure 3. Patients who
used either oral contraceptives or oral HRT were
nic venous thrombosis, in approximately 50% of
Budd-Chiari syndrome cases and in 25% of por-
tal vein thrombosis cases is associated with the
presence of an MPN7,10-15. Both arterial and ve-
nous thrombotic events may develop in the pre-
clinical phase of the MPN or during the haemato-
logical follow-up period7,16,17. Additional possible
risk factors have recently been investigated with
a view to improving the prediction of thrombotic
events in MPNs, with therapeutic strategies
based on the thrombotic risk7-9,18-20. The 2013 up-
dated risk stratification data for thrombosis in PV
and ET not only consider the well-known roles
of advanced age and prior thromboses, but addi-
tionally suggest the importance of the main car-
diovascular (CV) risk factors (smoking, hyper-
tension and diabetes mellitus) and JAK2 V617F
mutation positivity. But to date CV risk factors
have not been integrated in the widely used risk-
guided management of ET or PV. It is still based
only on two risk factors (age and a prior throm-
botic event), and classifies the patients into low-
(age < 60 years, without a prior thrombotic
event) and high-risk (age > 60 years and/or with
a prior thrombotic event) categories9,21.
In the relevant literature, there are only limit-
ed data concerning the investigation of throm-
botic complications separately in female ET and
PV patients and, we therefore, set out to investi-
gate the prevalence of cardiovascular (myocar-
dial infarction), cerebrovascular (ischaemic
stroke or transient ischaemic attack) and venous
thrombotic events before and after the haemato-
logical diagnosis of PV and ET in a female pop-
ulation. A further aim was to evaluate the im-
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Figure 1. Distribution of thrombotic complications before ET/PV diagnosis and in the follow-up period. Abbreviations: TIA,
transient ischaemic attack; MI, myocardial infarct.
Figure 2. Distribution of the enrolled ET/PV patients with CV risk factors.
excluded from the study. Information relating to
an inherited thrombophilic state was not report-
ed. Further data were collected from the medical
data files, and all the haematological results were
reviewed. The cardiovascular (myocardial infarc-
tion), cerebrovascular (ischaemic stroke or a
transient ischaemic attack) and other venous
thrombotic events (such as deep vein thrombosis
or pulmonary embolism thromboses, and cere-
bral sinus and venous thromboses) before and af-
ter the haematological diagnosis were collected.
To evaluate the impact of major CV risk factors
on thrombotic events, hypertension (> 140/80
mmHg), cigarette smoking, diabetes mellitus,
obesity (BMI > 30 kg/m2) and hyperlipidaemia
(hypercholesterolaemia or hypertriglyceridaemia
or both) were also assessed in each patient. The
haematological management strategy was based
on the current risk-oriented recommendations.
Low-risk patients participated in anti-platelet
3813
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therapy if it was necessary, while high-risk pa-
tients received cytoreductive drugs (e.g. hydrox-
yurea) alone or in combination with antiplatelet
therapy21. Phlebotomy was recommended for pa-
tients diagnosed with PV at low risk and before
the cytoreductive treatment in high risk PV pa-
tients to reach the recommended target haemat-
ocrit level of 0.40 and 0.45. The study was ap-
proved by the Regional and Institutional Human
Medical Biological Research Ethics Committee.
No informed consent was required. The study
was conducted according to the Declaration of
Helsinki.
Laboratory Methods
Routine blood analysis with automated blood
count equipment was performed as part of the di-
agnosis protocol. Genomic DNA was isolated
from EDTA-stabilized peripheral blood samples
and screened for JAK2 V617F with an allele-spe-
cific PCR method22.
Statistical Analysis
Data were collected with Microsoft Office Ex-
cel, and statistical analyses were performed with
Statsoft Statistica v 9.1 and SPSS 20.0.0.2 software
(SPSS Inc., Chicago, IL, USA). Multivariate bina-
ry logistic regression was used to estimate the par-
tial effects of age, prior thrombotic events, leuko-
cytosis at haematological diagnosis, the JAK2
V617F mutation, and the presence of two or more
CV risk factors on the probability of thrombotic
events, and the potential influence of cytoreductive
(hydroxyurea) and antiplatelet therapy on the sub-
sequent thrombotic events after the haematological
diagnosis. For an evaluation of the impact of treat-
ment, we additionally computed the difference in
Figure 3. Distribution by age of (A) diagnosed ET and PV cases, (B) cardiovascular risk factors, and (C) thrombotic compli-
cations, during the follow-up period. Abbreviations: ET: essential thrombocythaemia; PV: polycythaemia vera; CV: cardiovas-
cular.
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the number of thrombotic events after and before
the diagnosis for each patient. We tested the rela-
tionship between the treatment and the change in
the number of thrombotic events by Fisher’s exact
test, Somers’ D test and the significance test of
Spearman’s coefficient.
The overall effects of the major CV risk fac-
tors (hypertension, cigarette smoking, diabetes
mellitus, obesity and hyperlipidaemia) on the
thrombotic events and the effect of the JAK2
V617F mutation on thrombotic events after the
haematological diagnosis were investigated by
means of the Mann-Whitney test in subgroups of
patients who had or had not suffered thrombotic
events. The Kaplan-Meier method was carried
out, followed by the log-rank test to evaluate the
probability of thrombosis-free survival of the pa-
tients in the cohort23. In this analysis, the data on
patients with at most one CV risk factor and
those with two or more CV risk factors were
compared. p < 0.05 was considered statistically
significant.
Results
JAK2 V617F positivity was proven in 84 pa-
tients (65.63%). A total of 55 thrombotic events
were recorded in the history of 37 patients with
42 events (32.8%) before the clinical diagnosis of
the neoplasms: ischaemic stroke or a transient is-
chaemic attack in 13 patients (10.16%), myocar-
dial infarction in 15 patients (11.72%), and ve-
nous thrombotic events (deep vein thrombosis,
portal vein thrombosis or splenic vein thrombo-
sis) in 14 patients (10.94%). During the haemato-
logical follow-up period, 13 (10.2%) new throm-
botic events were recorded: ischaemic stroke or a
transient ischaemic attack in 11 patients (8.59%)
and a venous thrombotic event (pulmonary em-
bolism) or a CV event in one patient each
(0.78%) (Figure 1). 70 patients (54.7%) exhibited
high blood pressure, 17 patients (13.3%) hyper-
lipidaemia and, 17 patients (13.3%) diabetes
mellitus, and 15 patients (11.7%) were cigarette
smokers. 96 women (75%) had a normal body
weight, and the remaining 32 (25%) were obese
(BMI > 30 kg/m2) (Figure 2).
Mann-Whitney univariate tests and multivari-
ate binary logistic regression were run to com-
pare two subgroups, distinguished by the pres-
ence or absence of major thrombotic events. This
revealed that the presence of two or more CV
risk factors (univariate: p = 0.011; multivariate:
relative risk: 4.728 95% CI 1.312-17.040; p =
0.018) significantly increased the risk of throm-
botic events during the follow-up period of the
PV/ET neoplasms. Statistical analyses demon-
strated a significant overall association between
an enhanced thrombotic tendency and high blood
pressure (p = 0.001), hyperlipidaemia (p = 0.005)
and tobacco use (p = 0.051), whereas diabetes
mellitus (p = 0.635) and obesity (p = 0.866) were
not associated with a significantly increased risk
of thrombosis. Besides the JAK2 V617F muta-
tion (univariate: p = 0.367; multivariate: relative
risk: 1.428, 95% CI 0.316-6.460; p = 0.643) and
the well-known standard risk factors (univariate:
p = 0.816 multivariate: relative risk: 0.848 95%
CI 0.239-3.004; p = 0.798) (Table II), leukocyto-
sis and the potential influence of the therapy ap-
plied on the thrombotic events in the follow-up
period was analysed.
Analyses of the cases with a leukocyte count >
11.1 G/L measured at the time of the haemato-
logical diagnosis resulted in a non-significant
tendency from the aspect of further thrombotic
complications in the follow-up period (univari-
ate: p = 0.424; multivariate: relative risk: 1.407,
95% CI 0.359-5.507; p = 0.624) (Table II).
In the two subgroups distinguished by the
presence or absence of major thrombotic events
among the patients treated with antiplatelets
(univariate: p = 0.94) or with antiplatelets with
hydroxurea (univariate: p = 0.405) and phle-
botomy in PV (univariate: p = 0.614; multivari-
ate: relative risk: 0.798, 95% CI 0.172-3.710; p
= 0.773), no significant effect on the presence
of thrombosis in the follow-up period was ob-
served. Although the tendency observed in the
case of phlebotomy was non-significant, the
multivariate analysis relative risk data indirectly
suggest that phlebotomy may have a beneficial
effect on thrombotic complications in the fol-
low-up period. We, additionally, computed the
difference in the number of thrombotic events
after and before the diagnosis for each patient
and, then, tested the relationship between the
treatment and the change in the number of
thrombotic events by means of Fisher’s exact
test, Somers’ D test and the significance test of
Spearman’s coefficient with a view to obtaining
a robust result. Overall, when all of the treat-
ments were considered together, there was a
significant (Fisher’s exact test p-value: 0.061,
Somers’ D test p-value: 0.044, Spearman’s coef-
ficient p-value: 0.044) impact of the treatment
in decreasing the number of thrombotic events.
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However, the results for the separately analysed
treatments proved to be heterogeneous, typical-
ly with a non-significant decreasing impact (p-
values in the range 0.194-0.625).
For further analyses, Kaplan–Meier curves and
log rank tests (Mantel-Cox) were run to compare
the thrombosis-free survival of the patients. A
significant difference was observed (p = 0.005)
between patients with at most one CV risk factor
(n=79) and those with two or more CV risk fac-
tors (n=47) (Figure 4).
Discussion
In view of the fact that the life expectancy of
PV and ET patients is strongly affected by
thrombotic events, an investigation of both con-
ventional and additional possible risk factors of
thrombotic events in women appears to be of ap-
preciable importance.
Multicentric investigations (mostly in the peri-
od 2010-2013), have led to the view that addi-
tional thrombotic risk factors should also be con-
sidered in the currently accepted thrombosis risk-
guided management7,9,16,24-30. The roles of the
JAK2 V617F mutation and cardiovascular risk
factors (at least one CV risk factor, hypertension
and/or diabetes and/or active tobacco) are be-
lieved to be the most important, while the poten-
tial role of the leukocyte count measured at diag-
Comparison of patients who did or did not suffer subsequent thrombotic events
Mann-whitney Multivariate binary
univariate analysis logistic regression analysis
Variables p p Relative risk Hazard ratio 95% CI
At least one CV risk factor present
High blood pressure 0.001** ND
Hyperlipidaemia 0.005** ND
Cigarette smoking 0.051* ND
Diabetes mellitus 0.635 ND
Obesity 0.866 ND
Two or more CV risk factors present 0.011** 0.018** 4.728 1.312 17.040
Conventional MPN risk factors 0.816 0.798 0.848 0.239 3.004
advanced age (over 60) or a
prior thrombotic event
JAK2 V617F mutation 0.367 0.643 1.428 0.316 6.460
WBC > 11.1 G/L 0.424 0.624 1.407 0.359 5.507
Table II. Mann-Whitney test and multivariate binary logistic regression results relating to the overall and partial effects on the
probability of thrombotic events of the suggested cardiovascular risk factors, conventional MPN risk factors, the JAK2 V617F
mutation, and a white blood cell count over 11.1 G/L in the comparison of ET patient subgroups who did or who did not suffer
subsequent thrombotic events.
Significant differences at 10% are marked by*, and at 5% by**. Abbreviations: CV: cardiovascular risk; ND: not determined;
MPN: myeloproliferative neoplasm; WBC: white blood cell count.
Figure 4. Probability of thrombosis-free survival in the
haematological follow-up period in the observed subgroups.
Abbreviation: CV: cardiovascular.
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nosis is still controversial7,9,16,24-30. However, the
currently widely used risk stratification in the
thrombosis risk management strategy of ET/PV
is still based on only two risk factors (age and a
prior thrombotic event), and classifies the pa-
tients into low- (age < 60 years, without a prior
thrombotic event) and high-risk (age > 60 years
and/or with prior thrombotic event) categories21.
Our findings on female patients indicated that
CV risk factors, and especially a high blood pres-
sure and cigarette smoking (similarly as in a mul-
ticentric female and male MPN population) and
hyperlipidaemia, pose a significantly higher risk
of thrombotic events after the diagnosis of PV or
ET, while in the case of diabetes mellitus we did
not find a significant association. In cases in
which the presence of two or more CV risk fac-
tors was observed, a significantly higher risk of
thrombosis was also seen. Moreover, a signifi-
cant difference was revealed in the thrombosis-
free survival between patients with at most one
CV risk factor and those with two or more CV
risk factors.
The 2013 updated risk stratification for throm-
bosis in MPN patients emphasized the prognostic
role of the presence of the JAK2 V617F
mutation9. Our female patients were predomi-
nantly (65.63%) JAK2 V617F mutation-positive,
but our results did not indicate that the presence
of the JAK2 V617F mutation was statistically as-
sociated with an increased prevalence of throm-
botic events. Larger studies on female and male
ET/PV populations together have indicated that
the JAK2 V617F mutation has a significant role
in the prediction of subsequent thrombosis in
ET/PV, whereas our current findings on a female
population were rather paradoxical from this as-
pect9,25. The role of the JAK2 V617F mutation in
the subsequent thrombotic complications did not
proved to be statistically significant in current fe-
male population. We suggest that the number of
patients involved might be determinative as con-
cerns a clear evaluation of the presence of the
JAK2 V617F mutation and the prediction of
thrombosis.
Falanga et al31 demonstrated that activation of
the circulating polymorphonuclear leukocytes
occurs in MPNs and plays a possible role in the
thrombotic complications of the patients. Some
previous studies32-34 have indicated an association
between leukocytosis at diagnosis and later
thrombotic complications, although other reports
did not confirm this. Gangat et al35 concluded
that the leukocyte count at the time of the haema-
tological diagnosis, defined by a level of either
15 or 9.4 G/L did not appear to be predictive of a
subsequent thrombotic event, whereas Carobbio
et al36 considered that the role of leukocytes
above a median level of 8.7 G/L in predicting
thrombotic complications was evident in untreat-
ed low-risk as compared with treated high-risk
patients. In our female population, a leukocyte
count > 11 G/L at the time of the ET/PV diagno-
sis did not appear to have an influence on the risk
of subsequent thrombosis: only a non-significant
difference was observed between the patients
who suffered subsequent thrombotic complica-
tions and those who did not.
We consider that the issue of MPNs, with spe-
cial focus on women and thromboses, should not
be neglected with regard to other, particularly gy-
naecological and obstetric complications. In the
relevant literature, a registry for observational
studies has already been created concerning
pregnancy in chronic Philadelphia chromosome-
negative MPNs, but only one large study has
demonstrated that oral contraceptives are associ-
ated with an increased risk of venous thrombosis
in one type of MPN, ET, while in PV no data
have been reported37-39. These findings suggest
that spontaneous abortion or major maternal
complications such as pre-eclampsia, postpartum
pulmonary embolism and extensive postpartum
haemorrhage may occur more frequently in PV
than in other MPNs38,39. However, the available
evidence relating to oestrogen-based hormone
treatment is insufficient either to support or to re-
fute an association between oestrogen-based hor-
mone treatment and the risk of thrombosis in
MPN37. In view of its importance, it would be in-
teresting to conduct large-scale studies on female
patients with PV or ET from the aspect of the
prevention of thrombotic events, particularly
through comparisons of the risk status of MPN
patients who use or do not use oral contracep-
tives or HRT.
Conclusions
Female MPN patients who display cardiovas-
cular risk factors (especially high blood pressure,
hyperlipidaemia and cigarette smoking) may be
at a higher risk of thrombotic events and require
special consideration in the prevention and man-
agement of thrombotic events. The roles of the
JAK2 V617F mutation and leukocytosis in the
subsequent thrombotic complications did not
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proved to be statistically significant in this fe-
male population. Due to the relatively low num-
ber of enrolled female PV and ET patients in this
single-centre study, the findings do not permit
definitive recommendations, but call for prospec-
tive multicentric studies on female ET and PV
populations.
–––––––––––––––––-–––
Conflict of Interest
The Authors declare that there are no conflicts of interest.
References
1) MARTINELLI I, DE STEFANO V, MANNUCCI PM. Inherited
risk factors for venous thromboembolism. Nat Rev
Cardiol 2014; 11: 140-156.
2) SIMIONI P, TORMENE D, SPIEZIA L, TOGNIN G, ROSSETTO
V, RADU C, PRANDONI P. Inherited thrombophilia and
venous thromboembolism. Semin Thromb He-
most 2006; 32: 700-708.
3) RAMBALDI MP, MECACCI F, GUASCHINO S, PAIDAS MJ. In-
herited and acquired thrombophilias. Reprod Sci
2014; 21: 167-182.
4) BARBUI T, THIELE J, PASSAMONTI F, RUMI E, BOVERI E,
RUGGERI M, RODEGHIERO F, D'AMORE ES, RANDI ML,
BERTOZZI I, MARINO F, VANNUCCHI AM, ANTONIOLI E,
CARRAI V, GISSLINGER H, BUXHOFER-AUSCH V, MÜLLAUER
L, CAROBBIO A, GIANATTI A, GANGAT N, HANSON CA,
TEFFERI A. Survival and disease progression in es-
sential thrombocythemia are significantly influ-
enced by accurate morphologic diagnosis: an in-
ternational study. J Clin Oncol 2011; 29: 3179-
3184.
5) CHIM CS, KWONG YL, LIE AK, MA SK, CHAN CC,
WONG LG, KHO BC, LEE HK, SIM JP, CHAN CH, CHAN
JC, YEUNG YM, LAW M, LIANG R. Long-term outcome
of 231 patients with essential thrombocythemia:
prognostic factors for thrombosis, bleeding,
myelofibrosis, and leukemia. Arch Intern Med
2005; 165: 2651-2658.
6) TEFFERI A, VARDIMAN JW. Classification and diagno-
sis of myeloproliferative neoplasms: the 2008
World Health Organization criteria and point-of-
care diagnostic algorithms. Leukemia 2008; 22:
14-22.
7) FALANGA A, MARCHETTI M. Thrombotic disease in the
myeloproliferative neoplasms. Hematology Am
Soc Hematol Educ Program 2012; 2012: 571-581.
8) TEFFERI A. Polycythemia vera and essential throm-
bocythemia: 2012 update on diagnosis, risk strati-
fication, and management. Am J Hematol 2012;
87: 285-293.
9) TEFFERI A. Polycythemia vera and essential throm-
bocythemia: 2013 update on diagnosis, risk-strati-
fication, and management. Am J Hematol 2013;
88: 507-516.
3817
Rare acquired thrombophilia in women
10) KILADJIAN JJ, CERVANTES F, LEEBEEK FW, MARZAC C,
CASSINAT B, CHEVRET S, CAZALS-HATEM D, PLESSIER A,
GARCIA-PAGAN JC, DARWISH MURAD S, RAFFA S, JANSSEN
HL, GARDIN C, CEREJA S, TONETTI C, GIRAUDIER S, CON-
DAT B, CASADEVALL N, FENAUX P, VALLA DC. The im-
pact of JAK2 and MPL mutations on diagnosis
and prognosis of splanchnic vein thrombosis: a
report on 241 cases. Blood 2008; 111: 4922-
4929.
11) REIKVAM H, TIU RV. Venous thromboembolism in
patients with essential thrombocythemia and
polycythemia vera. Leukemia 2012; 26: 563-571.
12) BRECCIA M, MORANO SG, D'ANDREA M, RUSSO E,
D'ELIA GM, ALIMENA G. Budd-Chiari syndrome as
the first manifestation of polycythemia vera in
young women with inherited thrombophilic state:
an aggressive form of myeloproliferative disorder
requiring multidisciplinary management. Eur J
Haematol 2005; 75: 396-400.
13) VALLA D, CASADEVALL N, LACOMBE C, VARET B, GOLD-
WASSER E, FRANCO D, MAILLARD JN, PARIENTE EA, LEP-
ORRIER M, RUEFF B, ET AL. Primary myeloproliferative
disorder and hepatic vein thrombosis. A prospec-
tive study of erythroid colony formation in vitro in
20 patients with Budd-Chiari syndrome. Ann In-
tern Med 1985; 103: 329-334.
14) ANIA BJ, SUMAN VJ, SOBELL JL, CODD MB, SILVERSTEIN
MN, MELTON LJ, 3RD. Trends in the incidence of
polycythemia vera among Olmsted County, Min-
nesota residents, 1935-1989. Am J Hematol
1994; 47: 89-93.
15) ROSA A, CIPOLLONE L, BERTAZZONI G. Venous throm-
bosis in emergency department: diagnosis, treat-
ment, and disposition. Eur Rev Med Pharmacol
Sci 2012; 16(Suppl 1): 48-56.
16) TEFFERI A, ELLIOTT M. Thrombosis in myeloprolifera-
tive disorders: prevalence, prognostic factors, and
the role of leukocytes and JAK2V617F. Semin
Thromb Hemost 2007; 33: 313-320.
17) ZORASTER RM, RISON RA. Acute embolic cerebral is-
chemia as an initial presentation of polycythemia
vera: a case report. J Med Case Rep 2013; 7:
131.
18) BARBUI T, FINAZZI G, FALANGA A. Myeloproliferative
neoplasms and thrombosis. Blood 2013; .
19) ANDRIKOVICS H, MEGGYESI N, SZILVASI A, TAMASKA J,
HALM G, LUEFF S, NAHAJEVSZKY S, EGYED M, VARKONYI
J, MIKALA G, SIPOS A, KALASZ L, MASSZI T, TORDAI A.
HFE C282Y mutation as a genetic modifier influ-
encing disease susceptibility for chronic myelo-
proliferative disease. Cancer Epidemiol Biomark-
ers Prev 2009; 18: 929-934.
20) ANDRIKOVICS H, SZILVASI A, MEGGYESI N, KIRALY V, HALM
G, LUEFF S, NAHAJEVSZKY S, MIKALA G, SIPOS A, LOVAS
N, CSUKLY Z, MÁTRAI Z, TAMÁSKA J, TORDAI A, MASSZI T.
[Role of the activating mutation Val617Phe of
Janus kinase 2 gene in myeloproliferative dis-
eases and significance of its detection]. Orv Hetil
2007; 148: 203-210.
21) BARBUI T, BAROSI G, GROSSI A, GUGLIOTTA L, LIBERATO
LN, MARCHETTI M, MAZZUCCONI MG, RODEGHIERO F,
3818
É. Pósfai, I. Marton, Z. Kiss-László, B. Kotosz, M. Széll, Z. Borbényi
TURA S. Practice guidelines for the therapy of es-
sential thrombocythemia. A statement from the
Italian Society of Hematology, the Italian Society
of Experimental Hematology and the Italian
Group for Bone Marrow Transplantation. Haema-
tologica 2004; 89: 215-232.
22) BAXTER EJ, SCOTT LM, CAMPBELL PJ, EAST C,
FOUROUCLAS N, SWANTON S, VASSILIOU GS, BENCH AJ,
BOYD EM, CURTIN N, SCOTT MA, ERBER WN, GREEN
AR; CANCER GENOME PROJECT. Acquired mutation of
the tyrosine kinase JAK2 in human myeloprolifer-
ative disorders. Lancet 2005; 365: 1054-1061.
23) HILL AB, ED. A short textbook of medical statistics.
London: Hodder and Stoughton; 1984: p. 170.
24) Birgegard G. Pharmacological management of
essential thrombocythemia. Expert Opin Pharma-
cother 2013; 14:1295-1306.
25) BARBUI T, FINAZZI G, CAROBBIO A, THIELE J, PASSAMONTI F,
RUMI E, RUGGERI M, RODEGHIERO F, RANDI ML, BERTOZZI I,
GISSLINGER H, BUXHOFER-AUSCH V, DE STEFANO V, BETTI S,
RAMBALDI A, VANNUCCHI AM, TEFFERI A. Development
and validation of an International Prognostic Score
of thrombosis in World Health Organization-essen-
tial thrombocythemia (IPSET-thrombosis). Blood
2012; 120: 5128-5133; quiz 5252.
26) BARBUI T, BAROSI G, BIRGEGARD G, CERVANTES F, FINAZZI
G, GRIESSHAMMER M, HARRISON C, HASSELBALCH HC,
HEHLMANN R, HOFFMAN R, KILADJIAN JJ, KRÖGER N,
MESA R, MCMULLIN MF, PARDANANI A, PASSAMONTI F,
VANNUCCHI AM, REITER A, SILVER RT, VERSTOVSEK S,
TEFFERI A; EUROPEAN LEUKEMIANET. Philadelphia-neg-
ative classical myeloproliferative neoplasms: criti-
cal concepts and management recommendations
from European LeukemiaNet. J Clin Oncol 2011;
29: 761-770.
27) CAROBBIO A, THIELE J, PASSAMONTI F, RUMI E, RUGGERI
M, RODEGHIERO F, RANDI ML, BERTOZZI I, VANNUCCHI
AM, ANTONIOLI E, GISSLINGER H, BUXHOFER-AUSCH V,
FINAZZI G, GANGAT N, TEFFERI A, BARBUI T. Risk fac-
tors for arterial and venous thrombosis in WHO-
defined essential thrombocythemia: an interna-
tional study of 891 patients. Blood 2011; 117:
5857-5859.
28) TEFFERI A. Polycythemia vera and essential throm-
bocythemia: 2012 update on diagnosis, risk strati-
fication, and management. Am J Hematol 2012;
87: 284-293.
29) TEFFERI A, BARBUI T. Personalized management of
essential thrombocythemia-application of recent
evidence to clinical practice. Leukemia 2013; .
30) LEE HS, PARK LC, LEE EM, LEE SJ, SHIN SH, IM H, DO
KM, KIM EJ, YE BJ, SONG MK, KIM SH, LEE SM, LEE
WS, KIM YS. Incidence rates and risk factors for
vascular events in patients with essential throm-
bocythemia: a multicenter study from Korea. Clin
Lymphoma Myeloma Leuk 2012; 12: 70-75.
31) FALANGA A, MARCHETTI M, VIGNOLI A, BALDUCCI D,
BARBUI T. Leukocyte-platelet interaction in patients
with essential thrombocythemia and polycythemia
vera. Exp Hematol 2005; 33: 523-530.
32) CAROBBIO A, FINAZZI G, ANTONIOLI E, GUGLIELMELLI P,
VANNUCCHI AM, DELAINI F, GUERINI V, RUGGERI M,
RODEGHIERO F, RAMBALDI A, BARBUI T. Thrombocyto-
sis and leukocytosis interaction in vascular com-
plications of essential thrombocythemia. Blood
2008; 112: 3135-3137.
33) PASSAMONTI F, RUMI E, PASCUTTO C, CAZZOLA M, LAZ-
ZARINO M. Increase in leukocyte count over time
predicts thrombosis in patients with low-risk es-
sential thrombocythemia. J Thromb Haemost
2009; 7: 1587-1589.
34) CAMPBELL PJ, MACLEAN C, BEER PA, BUCK G, WHEAT-
LEY K, KILADJIAN JJ, FORSYTH C, HARRISON CN, GREEN
AR. Correlation of blood counts with vascular
complications in essential thrombocythemia:
analysis of the prospective PT1 cohort. Blood
2012; 120: 1409-1411.
35) GANGAT N, WOLANSKYJ AP, SCHWAGER SM, HANSON
CA, TEFFERI A. Leukocytosis at diagnosis and the
risk of subsequent thrombosis in patients with
low-risk essential thrombocythemia and poly-
cythemia vera. Cancer 2009; 115: 5740-5745.
36) CAROBBIO A, FINAZZI G, GUERINI V, SPINELLI O, DELAINI
F, MARCHIOLI R, BORRELLI G, RAMBALDI A, BARBUI T.
Leukocytosis is a risk factor for thrombosis in es-
sential thrombocythemia: interaction with treat-
ment, standard risk factors, and Jak2 mutation
status. Blood 2007; 109: 2310-2313.
37) GANGAT N, WOLANSKYJ AP, SCHWAGER SM, MESA RA,
TEFFERI A. Estrogen-based hormone therapy and
thrombosis risk in women with essential thrombo-
cythemia. Cancer 2006; 106: 2406-2411.
38) GRIESSHAMMER M, STRUVE S, HARRISON CM. Essential
thrombocythemia/polycythemia vera and preg-
nancy: the need for an observational study in Eu-
rope. Semin Thromb Hemost 2006; 32: 422-429.
39) GRIESSHAMMER M, STRUVE S, BARBUI T. Management
of Philadelphia negative chronic myeloprolifera-
tive disorders in pregnancy. Blood Rev 2008; 22:
235-245.
